Protege Biomedical, LLC v. Duff & Phelps Securities, LLC

CourtDistrict Court, D. Minnesota
DecidedSeptember 29, 2020
Docket0:19-cv-03152
StatusUnknown

This text of Protege Biomedical, LLC v. Duff & Phelps Securities, LLC (Protege Biomedical, LLC v. Duff & Phelps Securities, LLC) is published on Counsel Stack Legal Research, covering District Court, D. Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Protege Biomedical, LLC v. Duff & Phelps Securities, LLC, (mnd 2020).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MINNESOTA

PROTÉGÉ BIOMEDICAL, LLC, Civil No. 19-3152 (JRT/HB)

Plaintiff,

v. MEMORANDUM OPINION AND ORDER

DUFF & PHELPS SECURITIES, LLC, and PHILIP I. SMITH,

Defendants.

Jack Y. Perry and Kristine M. Boylan, TAFT STETTINIUS & HOLLISTER LLP, 2200 IDS Center, 80 South Eighth Street, Minneapolis, MN 55402, for Plaintiff.

Stephen V. D’Amore, Ross J. Corbett, and Scott Ahmad, WINSTON & STRAWN LLP, 35 West Wacker Drive, Chicago, IL 60601; David R. Marshall, FREDRIKSON & BYRON, 200 South Sixth Street, Suite 4000, Minneapolis, MN 55402, for Defendants.

This action arises out of a contract dispute between Plaintiff Protégé Biomedical, LLC and Defendants Duff & Phelps, LLC and its employee Phillip Smith (collectively, “Defendants”). Defendants filed a Motion to Dismiss pursuant to Federal Rule of Civil Procedure 12(b)(6) and Plaintiffs filed a Motion to Remand pursuant to 28 U.S.C. § 1447(c). After the Court heard arguments on these motions, Protégé filed a Motion to Amend its Complaint, which was taken under advisement by the Magistrate Judge. Because Protégé fails to plead any colorable claim against Smith, the Court will find that Smith was fraudulently joined to the action and, consequently, will dismiss all of Protégé’s claims against him and deny Protégé’s Motion to Remand. Additionally, because Protégé

fails to state any plausible claim against Duff & Phelps, the Court will find that Protégé fails to allege any plausible claims against Duff & Phelps but will stay its Order dismissing Protégé’s Complaint until after the Magistrate Judge rules on whether Protégé’s post- argument Motion to Amend should be granted.

BACKGROUND

I. FACTUAL BACKGROUND

A. The Parties Protégé is a Minnesota LLC that was founded in 2011 by Michael and Susan

Wuollett. (Am. Notice of Removal at 2, Ex. 1 (“Compl.”) ¶¶ 4–5, Dec. 30, 2019, Docket No. 13.) Protege specializes in researching, inventing, and developing blood-clotting products. (Compl. ¶ 6.) Protégé’s products are available for sale on the animal-health

marketplace and have recently been cleared for sale in the human-health marketplace by the Food and Drug Administration (“FDA”). (Id. ¶ 7.) Protégé keeps certain information collected in its work as trade secrets. (Id. ¶ 8.) Duff & Phelps is a financial advising firm based in New York with an office located

in Minnesota. (Id. ¶ 10.) Phillip Smith is a Minnesota resident and the Managing Director of Duff & Phelps’s Healthcare Mergers and Acquisitions department. (Id. ¶¶ 11–12). Smith works out of

Duff & Phelps’s Minnesota office. (Id. ¶¶ 11–12.) B. The Engagement Agreement

In December 2017, Protégé contracted with Duff & Phelps to assist Protégé in its efforts to find a buyer for Protégé. (Id. ¶ 23, Ex. B (the “Engagement Agreement”).) The

Engagement Agreement included the following relevant provisions: 1. Confidentiality Clause

The Engagement Agreement included a confidentiality clause requiring Duff & Phelps to

keep confidential all nonpublic information provided to it by [Protégé] until the earlier to occur of (i) the date five years from the date of this Agreement or (ii) the date such information shall have been made publicly available by [Protégé] or by others without breach of a confidentiality agreement, and shall not disclose such information to third parties other than to such of its employees and advisors as D&P determines have a need to know in connection with this Agreement or a potential Transaction.

(Engagement Agreement ¶ 9.) 2. Choice of Law & Express Release of Fiduciary Duty

The Engagement Agreement included a choice-of-law provision choosing New York Law to govern the agreement, (Id. ¶ 16), and expressly noted that Duff & Phelps “is not and shall not be construed as a fiduciary of [Protégé] . . . .” (Id. ¶ 18.)

3. Indemnification and Corporate Liability Clause

The Engagement Agreement required Protégé to indemnify and hold harmless to “the fullest extent” of the law Duff & Phelps and its employees (“Indemnified Persons”) from all liability unless that liability is “judicially determined to have resulted primarily

and directly from D&P’s or such Indemnified Person's willful misconduct or gross negligence or related to a breach by D&P of this Agreement.” (Id., Schedule A ¶ A.) Additionally, the Engagement Agreement notes that “[t]he obligations of D&P are

solely corporate obligations. No director, officer, employee, agent, shareholder or controlling person of D&P shall be subjected to any liability to any person, nor will any such claim be asserted by or on behalf of any other party to this Agreement.” (Id., Schedule A ¶ E.)

C. The Non-Disclosure Agreement

On January 19, 2018, Duff & Phelps, through Smith, reached out to Doug Schillinger, a Managing Director at DW Healthcare Partners (“DWHP”), a private equity investment firm, who also sat on the Board of Directors of Z-Medica, to initiate a discussion about Z-Medica acquiring Protégé. (Compl. ¶ 13–16, 22, 82, Ex. E.) Z-Medica, like Protégé, manufactures and sells hemostatic blood-clotting products. (Id. ¶ 19.)

Protégé alleges that Duff & Phelps, acting through Smith, assumed Schillinger to be an agent of Z-Medica when it reached out to him. (Id. ¶ 82.) On January 23, 2018, Schillinger and Smith, acting on behalf of Protégé, signed a non-disclosure agreement (“the NDA”) for “Project Falcon,” an internal reference for

Protégé. (Id. ¶¶ 70, 83, Ex. D (the “NDA”).) Protégé alleges that the NDA was created by Duff & Phelps and made Duff & Phelps exclusively responsible for all communication between the “Buyer” and Protégé. (Compl. ¶¶ 70–71; NDA ¶ 10.) Even so, Protégé had

its own team of lawyers review, edit, and approve the NDA before authorizing Duff & Phelps to send the NDA to Schillinger to execute. (Aff. of Jack Y. Perry ¶ 3, Ex. X at 2–3, 6–16, Jan. 13, 2020, Docket No. 27–1.) Schillinger signed the NDA and sent it back to Duff & Phelps. The body of the NDA

does not identify either Z-Medica or DWHP, instead stating, “[t]he _________ (“Buyer”) is interested in obtaining information about [Protégé] in order to study the feasibility of Buyer’s purchase of [Protégé].” (NDA at 1.) Schillinger listed his company only as DWHP and his title as Managing Director below his signature on the NDA. (Id. at 5.) Despite this,

Protégé alleges Duff & Phelps continued to assume Schillinger was an agent for Z-Medica, making Z-Medica subject to the NDA. (Compl. ¶ 84.) To support this assertion, Protégé points to an email from Duff & Phelps employee Adam Stormoen to the Wuolletts informing them that “DW Healthcare/Zmedica” (sic) had signed the NDA. (Id., Ex. F.)

D. The Disclosure of Confidential Information, the Failed Deal, and the Cease-and- Desist Letter

On February 9, 2018, shortly after Schillinger executed the NDA, the Wuolletts attended a conference call with Schillinger and two directors from Z-Medica, along with

representatives from Duff & Phelps, including Smith, to discuss the possibility of Z-Medica acquiring Protégé. (Compl. ¶ 85.) Protégé alleges that Mike Wuollett, before disclosing Protégé’s confidential information on the call, stated that “[s]ince we're all under an

NDA,” he could discuss the confidential information. (Id.) Protégé alleges that no one from Z-Medica denied being subject to the NDA nor did Smith or anyone from Duff & Phelps say Z-Medica was not subject to the NDA.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Pullman Co. v. Jenkins
305 U.S. 534 (Supreme Court, 1939)
Papasan v. Allain
478 U.S. 265 (Supreme Court, 1986)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Porous Media Corporation v. Pall Corporation
186 F.3d 1077 (Eighth Circuit, 1999)
Kevin Murphy v. Aurora Loan Services
699 F.3d 1027 (Eighth Circuit, 2012)
Braden v. Wal-Mart Stores, Inc.
588 F.3d 585 (Eighth Circuit, 2009)
Gardner v. Conway
48 N.W.2d 788 (Supreme Court of Minnesota, 1951)
Togstad v. Vesely, Otto, Miller & Keefe
291 N.W.2d 686 (Supreme Court of Minnesota, 1980)
Tonking v. Port Authority of New York & New Jersey
821 N.E.2d 133 (New York Court of Appeals, 2004)
State v. Pero
590 N.W.2d 319 (Supreme Court of Minnesota, 1999)
Savoy Record Co. v. Cardinal Export Corp.
203 N.E.2d 206 (New York Court of Appeals, 1964)
LeRoy Smithrud v. City of St. Paul
746 F.3d 391 (Eighth Circuit, 2014)
Gore v. Trans World Airlines
210 F.3d 944 (Eighth Circuit, 2000)
Madison Equities, Inc. v. Robert L. Crockarell
889 N.W.2d 568 (Supreme Court of Minnesota, 2017)
Spinelli v. National Football League
903 F.3d 185 (Second Circuit, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
Protege Biomedical, LLC v. Duff & Phelps Securities, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/protege-biomedical-llc-v-duff-phelps-securities-llc-mnd-2020.